Effects of Cinnamomum Supplementation in Chronic Kidney Disease Patients - Trial NCT06286735

Timeline & Enrollment

Primary Outcome

Concentration of Nuclear factor kappa B (NF-KB)

Summary

Patients with chronic kidney disease (CKD) experience many complications related to
 inflammation and oxidative stress that are closely related to the progression of kidney
 failure and increased mortality. Furthermore, these patients may have intestinal dysbiosis
 associated with persistent uremia, generating greater production of uremic toxins arising
 from the metabolism of intestinal bacteria and also helping to maintain the inflammatory
 process and oxidative stress. In this context, some nutritional strategies have been proposed
 as an adjuvant therapeutic alternative to modulate inflammation and improve the antioxidant
 response of patients with CKD, and even more so to modulate the intestinal microbiota. Based
 on the consolidated knowledge of the role of nutrients and bioactive compounds on the
 expression of genes related to inflammation, oxidative stress, and also the modulation of the
 intestinal microbiota, cinnamon, a member of the Lauraceae family, has been widely used as a
 spice and traditional herbal medicine for centuries and has indicated beneficial benefits in
 cardiovascular diseases, obesity, diabetes. The bioactive compounds in cinnamomum, such as
 cinnamaldehyde, cinnamic acid, and cinnamate, can attenuate oxidative stress, inflammation,
 hyperglycemia, intestinal dysbiosis, and dyslipidemia, which are common complications in CKD
 patients. Therefore, the present project proposes a longitudinal clinical trial study that
 aims to evaluate the effects of cinnamomum on transcription factors and inflammatory markers,
 oxidative stress and modulation of intestinal health in patients with CKD on hemodialysis.

ICD-10 Classifications